



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/529,059	12/14/2005	William Marshall Stark	056646-5024	2559
9629 7590 03/18/2011 MORGAN LEWIS & BOCKIUS LLP 1111 PENNSYLVANIA AVENUE NW WASHINGTON, DC 20004				
EXAMINER				
CHOWDHURY, IQBAL HOSSAIN				
ART UNIT		PAPER NUMBER		
1652				
MAIL DATE		DELIVERY MODE		
03/18/2011		PAPER		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b>		<b>Applicant(s)</b>	
	10/529,059		STARK ET AL.	
	<b>Examiner</b>		<b>Art Unit</b>	
	IQBAL H. CHOWDHURY		1652	

  

**All Participants:**

(1) IQBAL H. CHOWDHURY.

(2) Todd Buck.

**Date of Interview:** 10 March 2011

**Type of Interview:**

☒ Telephonic

☐ Video Conference

☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☐ No

If Yes, provide a brief description: \_\_\_\_\_

**Part I.**

Rejection(s) discussed:

  

Claims discussed:

4, 47, 52, 54, 57-59, 67, 70

Prior art documents discussed:

  

**Part II.**

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

*See Continuation Sheet*

**Part III.**

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

  
  
  
  
  
  
  
  
  
  

/ANAND U DESAI/  
Primary Examiner, Art Unit 1656

**Status of Application:** After nonfinal(RCE)

(3) \_\_\_\_\_

(4) \_\_\_\_\_

**Time:** \_\_\_\_\_

  
  
  
  
  
  
  
  
  
  

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: There was an interview with the Applicants representative to amend the claims (see, proposed amendment as shown below) to place the application in condition for allowance, however, applicants representative did not agree with the proposed amendment.

Amend claims as shown below:

Claim 54 (Currently amended). The catalytic domain according to claim 70 wherein the mutations are [[correspond to]] R2A and E56K in Tn3 resolvase of SEQ ID NO: 2.

Claim 57 (Currently amended). The catalytic domain according to claim 70 wherein the mutations are [[correspond to]] R2A, E56K, D102Y, M103I and Q105L in Tn3 resolvase of SEQ ID NO: 2.

Claim 70 (Currently amended). An isolated catalytic domain of a serine recombinase which has been mutated at [[a]] positions [[corresponding to]] [[G101 of Tn3 resolvase of (SEQ ID NO: 2), and wherein said catalytic domain consists of mutations at a position corresponding to M103, R2, E56, G101, D102 and Q105 of SEQ ID NO: 2.

Claim 71 (New). An isolated catalytic domain of a serine recombinase which has been mutated, wherein said catalytic domain consists of mutations at [[a]] positions [[corresponding to]] M103, R2, E56, G101, D102, Q105, and anyone of either E124Q or E124A of Tn3 resolvase of SEQ ID NO: 2.

Claim 72 (New). An isolated catalytic domain of a serine recombinase which has been mutated, wherein said catalytic domain consists of mutations at [[a]] positions [[corresponding to]] M103, R2, E56, G101, D102, Q105, V107F, and anyone of either E124Q or E124A of Tn3 resolvase of SEQ ID NO: 2.

Cancel claim 52, 58 and 59.